(lp0
S'The 3 Most Important Numbers for Exelixis, Inc. Motley Fool - Mar 14, 2017 This PFS result was so impressive that Exelixis immediately moved forward with preparing a regulatory submission for Cabometyx as a first-line treatment of kidney cancer.'
p1
aS"Exelixis, Inc. Turns a Profit, but Don't Get Too Excited Motley Fool - Mar 1, 2017 Exelixis  reported fourth-quarter earnings on Monday showing solid growth in sales of Cabometyx. The biotech reported a profit for the quarter, but there were some extenuating circumstances that helped push Exelixis into the black.Company Update : Exelixis, Inc. Announces Clinical Trial ... - Smarter AnalystExelixis Announces Webcasts of Investor Conference Presentations in March - Yahoo Finance"
p2
aS'3 Factors That Drove Exelixis, Inc. Higher By 19% in February Motley Fool - Mar 7, 2017 Shares of Exelixis , a biopharmaceutical company focused on the development of medicines for the treatment of cancer, surged 19% in February, according to data from S&amp;P Global Market Intelligence.'
p3
aS"Insider Trading Activity Exelixis, Inc.   EVP Sold 6884 shares ... Market Exclusive - 4 hours ago Jeffrey Hessekiel , EVP of Exelixis, Inc.  reportedly Sold 6,884 shares of the company's stock at an average price of 21.02 for a total transaction amount of $144,701.68 SEC Form.Latest Stocks: William Blair Analysts Reduce Earnings Estimates for Exelixis ... - Petro Global News 24Smart Money Still Has Faith in Exelixis, Inc.  - Midway Monitor"
p4
aS'The Technical Chart Exelixis, Inc.  Is Speaking Volumes NY Stock News - 14 hours ago The technicals for Exelixis, Inc.  has spoken via its technical chart and the message is loud and clear. Based on that message, this is the relevant information necessary to make sense of that current setup.'
p5
aS'Advanced Accelerator Applications SA versus Exelixis Inc Head to Head Compare CML News - 16 hours ago Exelixis Inc has a higher fundamental rating then Advanced Accelerator Applications S.A. which has an impact on the head-to-head comparison.'
p6
aS'Form 4 EXELIXIS, INC. For: Mar 20 Filed by: FELDBAUM CARL B StreetInsider.com - Mar 21, 2017 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1. 1. Name and Address of Reporting Person *. FELDBAUM CARL B. , , . C/O EXELIXIS, INC. 210 E. GRAND AVE. &nbsp;...'
p7
aS'Exelixis to Present at the Needham &amp; Company Healthcare Conference on April 4 Business Wire  - Mar 6, 2017 SOUTH SAN FRANCISCO, Calif.----Exelixis, Inc.  today announced that Michael M. Morrissey, Ph.'
p8
aS"Exelixis, Inc.  Receives FDA Orphan Drug Designation for the Treatment ... Smarter Analyst - Mar 6, 2017 Exelixis, Inc.  announced that the FDA has granted orphan drug designation to cabozantinib for the treatment of hepatocellular carcinoma .Hot Stock to Watch: Exelixis, Inc.  - HugoPressExelixis, Inc. : What's the Story? - StockNewsJournal"
p9
aS"Why Analysts put forward these two stocks: Exelixis, Inc. , Staples, Inc ... The USA Commerce - Mar 27, 2017 Shares of Exelixis, Inc.  surged 2.95% to $20.91. During the trading on 03/24/2017, Company's stock ranged from $21.08 to $20.31."
p10
a.